RaQualia Pharma Inc.
4579・Growth Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The board consists of 6 directors (4 outside directors, outside ratio 66.7%), and an executive officer system has been introduced. A voluntary nomination and compensation committee has been established, chaired by an outside director. All directors achieved a 100% attendance rate at board meetings. Following approval at the ordinary general meeting of shareholders in March 2026, the board is scheduled to transition to a structure of 8 directors (6 outside directors).
Risk Management
Based on its Risk Management Regulations, the Company has established a Risk Management Committee (chaired by the Representative Director, with participation from executive officers and Audit and Supervisory Committee members), which meets semi-annually. It conducts assessment, response, management, and communication regarding compliance risk, reputational risk, operational risk, disaster risk, sustainability risk, and other risks. The Company has also entered into an advisory agreement with a law firm to address day-to-day legal matters.
Shareholder Returns
No dividend is currently being paid, and this policy remains unchanged. The annual dividend forecast for FY2026 (ending December 2026) is ¥0 (¥0 at the second-quarter end and ¥0 at year-end). The policy of prioritizing the strengthening of the financial base and the accumulation of retained earnings for research and development remains unchanged.
Dividend Policy
The Company will consider dividends comprehensively, taking into account the need to accumulate retained earnings to prepare for future research and development activities, once it becomes able to secure stable profits and has strengthened its financial base. If dividends are paid, the basic policy is a single year-end dividend, and the Articles of Incorporation also provide for interim dividend provisions. The annual dividend is ¥0 for both FY2025 (ending December 2025) and FY2026 (ending December 2026) (forecast).
ESG
Under the slogan "innovators for life," the company promotes drug discovery R&D linked to SDG Goal 3, "Good Health and Well-being." It has established a Sustainability Committee to deliberate on ESG basic policy and manage materiality. In terms of human capital, the company works on developing the specialized expertise of research personnel, industry-academia collaboration (e.g., with Nagoya University), and promoting work-life balance. Quantitative indicators and targets have not yet been set. The proportion of women in managerial positions is 13.6%, and the gender wage gap for all workers is 70.5% (at the reporting company).
Last updated: March 23, 2026